ENTOD Pharmaceuticals has introduced PresVu, a groundbreaking eye drop for treating presbyopia, in Mumbai. This innovative solution offers an alternative to reading glasses for those over 40 struggling with age-related blurry vision.
PresVu works by temporarily improving the eye’s lens flexibility, with effects noticeable within 15 minutes and lasting several hours. Priced at ₹345 per monthly vial, it’s an affordable option for many.
The eye drops underwent extensive clinical trials across India, involving 250 patients at 10 sites. Results showed optimal effectiveness for individuals aged 40-55 with mild to moderate presbyopia. The Drug Controller General of India (DCGI) granted approval following these successful trials.
ENTOD Pharmaceuticals plans to launch PresVu in early October, targeting not only the Indian market but also emerging markets in Africa and Southeast Asia. The company’s CEO, Nikkhil K. Masurkar, describes PresVu as a “revolutionary treatment for presbyopia.”
While promising, PresVu should only be used under an ophthalmologist’s guidance. This non-invasive treatment represents a significant advancement in eye care, potentially changing how millions manage their daily visual challenges.
To read more, click here.